, in a press note to the exchanges on Tuesday, informed that the company has launched Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (Tadalafil) Tablets in the United States market.
"Dr.Reddy's Tadalafil Tablets are available in 20mg with 60 count bottle size. Adcirca is a trademark of Eli Lilly and company," the pharma company added.
As per IMS Health data, the Adcirca brand and generic had US sales of ~$490mn MAT for the most recent twelve months ending November 2018.
Dr.Reddy's Laboratories Ltd's share price is currently at Rs2,619, up by Rs2.05 or 0.08%, from its previous close of Rs2,616.95 on the BSE.
The scrip opened at Rs2,625.70 and has touched a high and low of Rs2,674.40 and Rs2,586.45, respectively. So far, 7,48,979 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs43,457.30cr.